Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Catalent Inc (CTLT)

Catalent Inc (CTLT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,655,069
  • Shares Outstanding, K 179,964
  • Annual Sales, $ 4,828 M
  • Annual Income, $ 503,000 K
  • 60-Month Beta 1.24
  • Price/Sales 1.95
  • Price/Cash Flow 8.98
  • Price/Book 2.00
Trade CTLT with:

Options Overview Details

View History
  • Implied Volatility 55.95% ( +5.00%)
  • Historical Volatility 38.40%
  • IV Percentile 86%
  • IV Rank 59.00%
  • IV High 72.58% on 11/28/22
  • IV Low 32.02% on 04/01/22
  • Put/Call Vol Ratio 0.65
  • Today's Volume 99
  • Volume Avg (30-Day) 414
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 7,477
  • Open Int (30-Day) 8,055

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 0.64
  • Number of Estimates 7
  • High Estimate 0.73
  • Low Estimate 0.57
  • Prior Year 0.85
  • Growth Rate Est. (year over year) -24.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.92 +25.00%
on 12/28/22
54.12 -0.87%
on 01/27/23
+10.33 (+23.85%)
since 12/27/22
3-Month
40.69 +31.85%
on 11/22/22
67.20 -20.16%
on 10/28/22
-12.62 (-19.04%)
since 10/27/22
52-Week
40.69 +31.85%
on 11/22/22
115.33 -53.48%
on 07/29/22
-43.23 (-44.62%)
since 01/27/22

Most Recent Stories

More News
Taro Pharmaceutical (TARO) Lags Q3 Earnings and Revenue Estimates

Taro (TARO) delivered earnings and revenue surprises of -78.16% and 14.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

TARO : 30.50 (-0.33%)
CTLT : 53.65 (+2.64%)
Catalent, Inc. Announces Second Quarter Fiscal Year 2023 Earnings Conference Webcast

Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities,...

CTLT : 53.65 (+2.64%)
Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Ricardo Zayas as Senior Vice President, Operations,...

CTLT : 53.65 (+2.64%)
Catalent's (CTLT) New Deal to Utilize Its Zydis ODT Technology

Catalent's (CTLT) latest development and license agreement is expected to accelerate the administration of therapeutic doses of active drugs.

CAH : 76.48 (-1.80%)
MMSI : 69.94 (+0.60%)
AMN : 96.32 (-2.65%)
CTLT : 53.65 (+2.64%)
Avantor® and Catalent Enter into Multi-Year Supply and Services Agreement

/PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced...

AVTR : 24.10 (+1.18%)
CTLT : 53.65 (+2.64%)
Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate

Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, and Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic...

CTLT : 53.65 (+2.64%)
SRPT : 122.89 (-1.27%)
Catalent, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference

Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities,...

CTLT : 53.65 (+2.64%)
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 67.18 (+0.36%)
VRTX : 321.45 (+0.13%)
IBB : 137.23 (+0.05%)
CCXI : 51.99 (+0.06%)
CTLT : 53.65 (+2.64%)
XBI : 89.39 (+0.90%)
Stocks Settle Mixed as Energy Stocks Gain while Tech Stocks Slip

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday rose +0.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) rose +0.28%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) fell -0.11%. Stocks...

$SPX : 4,070.56 (+0.25%)
SPY : 405.68 (+0.23%)
$DOWI : 33,978.08 (+0.08%)
DIA : 339.61 (+0.07%)
$IUXX : 12,166.60 (+0.96%)
QQQ : 296.26 (+1.00%)
SLB : 56.97 (-0.87%)
HAL : 40.52 (-1.17%)
BKR : 31.30 (-1.57%)
COP : 123.61 (-0.83%)
PSX : 108.73 (-2.48%)
CVX : 179.45 (-4.44%)
Stocks Climb on Strength in Tech Stocks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.31%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.36%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.18%. Stocks...

$SPX : 4,070.56 (+0.25%)
SPY : 405.68 (+0.23%)
$DOWI : 33,978.08 (+0.08%)
DIA : 339.61 (+0.07%)
$IUXX : 12,166.60 (+0.96%)
QQQ : 296.26 (+1.00%)
MRNA : 189.35 (-2.01%)
LCID : 12.87 (+43.00%)
TTD : 51.95 (+4.42%)
ADBE : 370.71 (+1.34%)
AMZN : 102.24 (+3.04%)
CIEN : 51.03 (-0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Catalent, Inc. is a renowned global provider of advanced delivery technologies as well as development and manufacturing solutions for drugs (protein, cell, and gene therapy biologics) and consumer health products.

See More

Key Turning Points

3rd Resistance Point 56.73
2nd Resistance Point 55.42
1st Resistance Point 54.54
Last Price 53.65
1st Support Level 52.35
2nd Support Level 51.04
3rd Support Level 50.16

See More

52-Week High 115.33
Fibonacci 61.8% 86.82
Fibonacci 50% 78.01
Fibonacci 38.2% 69.20
Last Price 53.65
52-Week Low 40.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar